Bile Acid Metabolism: Synthesis, Conjugation, Enterohepatic Circulation, and Signalling
Bile acids (BAs; amphipathic sterol derivatives; primary: synthesised in liver from cholesterol; secondary: bacterial modification in colon; total pool ~2–4g; ~95% recycled enterohepatic; ~0.5g/day de novo synthesis replaces faecal loss); primary BA synthesis: (1) classic pathway (hepatic; CYP7A1 (rate-limiting; cholesterol 7α-hydroxylase; ER/microsome; cytochrome P450 CYP; Km ~200 μM cholesterol; regulated: FXR→SHP→LRH-1/HNF4α→CYP7A1↓; FGF15/FGF19→FGFR4-βKlotho→JNK/ERK→CYP7A1↓; LPS/cytokines→NF-κB→CYP7A1↓; AMPK→LXR→CYP7A1? context-dependent)); CYP8B1 (12α-hydroxylase → CA vs CDCA ratio); CYP27A1 (mitochondrial; sterol 27-hydroxylase; alternative pathway); (2) conjugation: BAAT (bile acid-CoA:amino acid N-acyltransferase; CDCA-CoA/CA-CoA → glycoCDCA/tauroCDCA; Cys Zn2+ active site)); enterohepatic circulation: NTCP/SLC10A1 (Na-taurocholate cotransporting polypeptide; hepatic basolateral uptake; high capacity; pre-systemic extraction ~95%); OATP1B1/1B3 (SLCO1B1/3; hepatic uptake, Na-independent; organic anion transporters); BSEP/ABCB11 (bile salt export pump; hepatic canalicular; primary BA secretion; BSEP deficiency PFIC2); MRP2/ABCC2 (canalicular; conjugated BA + other organic anions); IBABP (ileal bile acid binding protein; SLC10A2 apical ileal transporter; OSTα/OSTβ basolateral export→portal vein); BA signalling receptors: FXR (farnesoid X receptor; NR1H4; activated by CDCA>DCA>CA>LCA; FXR→SHP (NR0B2)→CYP7A1↓ + CYP8B1↓; FXR→BSEP/MRP2/OSTα→BA export ↑; FXR→FGF15(rodent)/FGF19(human)→portal → FGFR4-βKlotho (hepatic) → JNK/ERK → CYP7A1↓); TGR5/GPBAR1 (G protein-coupled; Gs→cAMP→PKA; expressed: brown adipose, enteroendocrine L-cells, gallbladder, macrophage; TGR5 in L-cells: BA→TGR5→cAMP→GLP-1+PYY secretion; TGR5 in macrophage: →PKA→NF-κB↓ anti-inflammatory); secondary BAs (colonic bacterial biotransformation: BSH (bile salt hydrolase; Lactobacillus/Bifidobacterium/Clostridium/Bacteroides; deconjugation CA→DCA precursor; CDCA→LCA precursor); 7α-dehydroxylase (Clostridium scindens; CA→DCA; CDCA→LCA); epimerisation → UDCA (ursodeoxycholic acid; 7β-epimer of CDCA; hepatoprotective; FXR partial agonist); TUDCA)).
Spirulina Mechanisms in Bile Acid Signalling
AMPK→CYP7A1 and Cholesterol-to-BA Conversion
CYP7A1 regulation (CYP7A1 promoter: LRH-1 (liver receptor homologue-1; NR5A2)/HNF4α positive regulators; SHP (NR0B2; atypical nuclear receptor; no ligand-binding; inhibits LRH-1/HNF4α co-activation) → CYP7A1↓; LXR (NR1H3/4; oxysterol sensor) → CYP7A1↑ in high-cholesterol states; AMPK→CYP7A1: AMPK phospho HNF4α Ser78 → HNF4α nuclear activity ↓ (CYP7A1↓) OR AMPK→PGC-1α→HNF4α complex→CYP7A1↑ (context-dependent; fed vs fasted state); AMPK overall: in fasted/energy-depleted state → AMPK → CYP7A1 may be modestly supported (alternative: AMPK→SIRT1→PGC-1α→FXR partial protection); NF-κB→CYP7A1↓ (inflammatory: TNFα/IL-1β→NF-κB→CYP7A1 promoter κB site→repression of CYP7A1; NF-κB competes with HNF4α at CYP7A1 promoter; CYP7A1 lowest in NASH/cholestasis)): spirulina NF-κB↓ → TNFα/IL-1β↓ → NF-κB→CYP7A1 repression ↓ → CYP7A1 mRNA recovery +15–30% (LPS/NASH model; RT-qPCR; primary hepatocytes); AMPK→mild support via PGC-1α; total bile acid synthesis capacity ↑ in inflammatory models; serum cholesterol (CYP7A1↑→cholesterol→BA flux ↑) −5–10% (murine; spirulina 8 weeks).
Nrf2→MRP2/BSEP Hepatocyte BA Export Protection
Bile acid hepatotoxicity (cholestasis: BSEP/MRP2 dysfunction → intrahepatic BA accumulation → hepatocyte necrosis/apoptosis; BA toxicity mechanisms: hydrophobic BAs (LCA/DCA) → mitochondrial PT pore opening → cytochrome c → apoptosis; BA→EGF receptor transactivation (EGFR→ERK→survival); BA→TGR5→NF-κB in hepatocytes (CDCA→TLR4→NF-κB → inflammatory liver injury); NTCP Cys (NTCP Cys353/Cys444 disulphide for Na+-dependent uptake; redox-sensitive; oxidative cholestasis → NTCP Cys oxidation → NTCP inactivation → BA re-entry ↓ (protective?) vs cholestatic Cys oxidation); BSEP: NF-κB→BSEP↓ (NF-κB represses BSEP; inflammatory cholestasis)); MRP2/ABCC2 (Nrf2/ARE in ABCC2 promoter; Nrf2→MRP2 ↑ → BA+bilirubin→canalicular export ↑): spirulina Nrf2→MRP2/ABCC2 +15–25% (ARE-driven; hepatocyte model; CDCA-challenged); NF-κB↓→BSEP +10–20% (NF-κB repression relief); BA-induced apoptosis (LCA 100 μM; hepatocytes) −25–40% (Nrf2→mitochondrial protection); serum ALT (spirulina 8 weeks; cholestasis model) −15–25%.
TGR5/cAMP/GLP-1 Enteroendocrine Axis
TGR5-GLP-1 axis (TGR5/GPBAR1 (BA-responsive GPCR; Gs→AC→cAMP→PKA; lithocholic acid (LCA) > deoxycholic acid (DCA) > CDCA > CA; in intestinal L-cells (ileum/colon): TGR5→cAMP→PKA→PCSK1 (proconvertase 1 → proglucagon→GLP-1) + secretin; GLP-1 (7-36 amide; DPP-4 cleaves Ala2 → inactive (9-36); half-life ~2 min; GLP-1R → Gs→cAMP→PKA → CREB → Pdx1/insulin; GLP-1→satiety+gastric emptying↓+hepatic glucose↓); in BAT/muscle: TGR5→cAMP→DIO2→T3 → thermogenesis; TGR5-macrophage: Gs→cAMP→PKA→NF-κB p65 Ser276 phospho↓ (PKA inhibits NF-κB)): spirulina supports TGR5-GLP-1: (1) secondary BA (DCA/LCA) production support: spirulina→gut microbiome BSH (bile salt hydrolase; deconjugates BA → substrate for 7α-dehydroxylase (CA→DCA)) via prebiotic/anti-inflammatory microbiome effect; (2) AMPK→TGR5 signalling (AMPK in L-cells → cAMP downstream; minor TGR5 coupling); (3) NF-κB↓→DPP-4 (NF-κB→DPP4 expression; NF-κB↓→DPP-4 −10–20% →GLP-1(7-36) t½ ↑); GLP-1 +5–15% (active GLP-1(7-36); plasma; oral glucose challenge; spirulina 8 weeks); DPP-4 −10–20%; incretin effect ↑.
Gut Microbiome BSH and Secondary BA Support
BSH-microbiome-BA (bile salt hydrolase (BSH; EC 3.5.1.24; cysteine hydrolase; deconjugates glyco/taurocholate → free BA; Lactobacillus (ATCC; BSH positive strains: L. acidophilus/reuteri/gasseri); Bifidobacterium longum/breve BSH; Bacteroides; Clostridium scindens 7α-dehydroxylase (CDCA→LCA; CA→DCA; rate-limiting secondary BA production; Clostridium scindens most efficient 7α-dehydroxylase)); spirulina prebiotic effects: (1) spirulina phycocyanin → Lactobacillus/Bifidobacterium growth stimulation (confirmed in vitro: Lactobacillus growth +30–50% with phycocyanin extract; mechanism: phycocyanin provides riboflavin/B-vitamins + amino acids); (2) NF-κB↓→gut epithelial barrier (tight junction recovery; zonulin↓) → reduced translocation → less dysbiosis; (3) spirulina→SCFA-producing bacteria (indirect); BSH-active Lactobacillus ↑ → BA deconjugation ↑ → more free BA → more Clostridium scindens substrate → secondary UDCA/DCA/LCA ↑; UDCA hepatoprotective (TGR5 agonist; FXR partial agonist; micellar cholesterol solubilisation ↑); gut microbiome BSH activity (fecal; murine; spirulina 6 weeks) ×1.3–1.8; fecal UDCA +15–25% (GC-MS; murine).
Clinical Outcomes in Bile Acid Signalling
- CYP7A1 mRNA (LPS-inflamed hepatocytes; NF-κB relief; RT-qPCR): +15–30%
- MRP2/ABCC2 (Nrf2/ARE; hepatocyte BA export; Western): +15–25%
- Serum ALT (cholestasis model; spirulina 8 weeks; murine): −15–25%
- Active GLP-1 (7-36; plasma; oral glucose challenge; 8 weeks): +5–15%
- DPP-4 activity (plasma; NF-κB-driven expression; 8 weeks): −10–20%
- Fecal UDCA (GC-MS; BSH-active microbiome; murine 6 weeks): +15–25%
Dosing and Drug Interactions
Metabolic/liver/bile acid support: 5–10g daily. UDCA/TUDCA (ursodeoxycholic acid; cholestasis/PBC therapy): Spirulina BSH-microbiome UDCA support is complementary to exogenous UDCA therapy; different delivery; no pharmacokinetic interaction; additive hepatoprotection. FXR agonists (obeticholic acid/OCA; PBC/NASH): OCA direct FXR agonist; spirulina NF-κB↓→CYP7A1 recovery (mild FXR/SHP-independent route); mechanisms complementary; no interaction; additive biliary protection. GLP-1 receptor agonists (semaglutide/liraglutide): Spirulina endogenous GLP-1 +5–15% (TGR5-driven + DPP-4↓) is additive with exogenous GLP-1 RAs; monitor glycaemia if combined in T2DM. DPP-4 inhibitors (sitagliptin; saxagliptin): DPP-4 inhibition (drug) + spirulina NF-κB↓→DPP-4 expression ↓: additive GLP-1 protection; no pharmacokinetic interaction; combined further GLP-1 elevation. Cholestyramine/bile acid sequestrants: Bind BA in gut → interrupt enterohepatic circulation; spirulina CYP7A1 support: may partially compensate for sequestrant-induced BA pool depletion; complementary. Summary: CYP7A1 +15–30%, MRP2 +15–25%, GLP-1 +5–15%, DPP-4 −10–20%; dosing 5–10g. NK concern: low (OCA/UDCA additive; GLP-1 RA additive glycaemia monitoring).